Mepolizumab

• BIOlogical treatment GRAdual Interval Longing in severe Asthma (BIO-GRAIL) Pending
  2025-524741-28-00 Phase IV 1 country Amsterdam UMC Stichting
• FESSnonFESS Recruiting
  2024-514632-24-02 Phase III/IV 1 country Rigshospitalet
• Biomarkers for the prediction of individual CRSwNP patients' responses to mepolizumab Recruiting
  2023-508069-34-01 Phase IV 1 country Amsterdam UMC
• the BIRDIE trial Recruiting
  2023-505839-12-01 Phase III 1 country Sint Franciscus Vlietland Groep Stichting
• eGPA and local inflammation within the ENT area Recruiting
  2023-508029-28-00 Phase IV 1 country Universitair Medisch Centrum Groningen
• Mepolizumab and in-office nasal polypectomy in patients with chronic rhinosinusitis (CRS). A three arm study. Recruiting
  2023-505426-34-01 Phase IV 1 country Instituto De Investigacion Marques De Valdecilla
• Complete remission study Ended
  2024-519628-25-00 Phase IV 1 country Rigshospitalet
• REIMAGINE – Real-world EvaluatIon of Mepolizumab in severe Asthma achievinG on treatment clinIcal remissioN, a prospEctive study. Ended
  2023-509026-21-00 Phase IV 6 countries Glaxosmithkline Research & Development Limited
• Biologic treatment of rhinosinusitis with nasal polyposis in real-world Danish patients - a direct comparison of dupilumab and mepolizumab Ended
  2022-502250-14-00 Phase IV 1 country Rigshospitalet
• A study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic … Ended
  2023-510019-20-00 Phase III 11 countries Glaxosmithkline Research & Development Limited
• Efficacy and Safety of Benralizumab in EGPA compared to mepolizumab. Ended
  2023-510248-19-00 Phase III 4 countries AstraZeneca AB
• Symptoms control and adhErenCe assessment during treatment with mepolizUmab new pREfilled devices. SECURE Ended
  2022-501029-19-00 Phase IV 1 country Hospices Civils De Lyon
• Study in Paediatrics with HypEREosinophilic syndrome (SPHERE) Ended
  2023-510110-36-00 Phase III 2 countries Glaxosmithkline Research & Development Limited
• Evaluation of MEpolizumab-based regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Eosinophilic … Ended
  2024-513653-75-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• Non-inferiority study of GSK3511294 (depemokimab) compared with mepolizumab or benralizumab in participants with severe asthma with an eosin… Ended
  2023-510230-84-00 Phase III 12 countries Glaxosmithkline Research & Development Limited
• Expanded access program for mepolizumab in subjects with hypereosinophilic syndrome. Ended
  2024-515247-28-00 Phase III 1 country Glaxosmithkline Research & Development Limited
• Predictive factors and magnitude of response to omalizumab and mepolizumab in allergic and eosinophilic severe asthma: PREDICTUMAB, an open-… Ended
  2024-516783-29-00 Phase IV 2 countries Cliniques Universitaires Saint-Luc

Showing 1–17 of 17 trials